Stocktoria
CRESCENT BIOPHARMA, INC. CBIO
CRESCENT BIOPHARMA, INC. (CBIO) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $10.8M at a -1419.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.835 |
| Retained earnings / assets | -0.715 |
| EBIT / assets | -0.635 |
| Equity / liabilities | 5.445 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CBIO | CRESCENT BIOPHARMA, INC. | 4/9 | 4.59 | — | — |
| JAGX | Jaguar Health, Inc. | 2/9 | — | — | -1.5% |
| JANX | Janux Therapeutics, Inc. | 2/9 | — | — | -5.6% |
| PRTA | PROTHENA CORP PUBLIC LTD CO | 1/9 | -5.98 | — | -92.8% |
| PGEN | PRECIGEN, INC. | 2/9 | — | — | — |
| PRLD | Prelude Therapeutics Inc | 3/9 | -17.29 | — | — |
| EVMN | Evommune, Inc. | 2/9 | 9.47 | — | — |
About CRESCENT BIOPHARMA, INC.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
FAQ
Is CBIO financially healthy?
CRESCENT BIOPHARMA, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CBIO pay a dividend?
No, CRESCENT BIOPHARMA, INC. does not currently pay a dividend.
How profitable is CBIO?
In FY2025, CRESCENT BIOPHARMA, INC. had a net margin of -1419.6% and a return on equity of -75.8%.
What is the analyst price target for CBIO?
The average Wall-Street price target for CRESCENT BIOPHARMA, INC. is $31.00, about 88.7% above the recent price, from 5 analysts (consensus: strong buy).
Is CBIO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CRESCENT BIOPHARMA, INC.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.